Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004153 | 1.00 | CYP2C19 (0.36) | CYP2C19GABRR1CYP1A2GRIK1GRIK2 | |
| SCHEMBL4585236 | 0.84 | GABRR1 (0.46) | GABRR1CYP1A2GRIK1GRIK2FOLH1 | |
| SCHEMBL4585237 | 0.84 | GABRR1 (0.46) | GABRR1CYP1A2GRIK1GRIK2FOLH1 | |
| SCHEMBL9331263 | 0.81 | GABRR1 (0.37) | GABRR1CYP1A2GRIK1GRIK2FOLH1 | |
| SCHEMBL9331250 | 0.81 | GABRR1 (0.37) | GABRR1CYP1A2GRIK1GRIK2FOLH1 | |
| SCHEMBL10394425 | 0.81 | GABRR1 (0.37) | GABRR1CYP1A2GRIK1GRIK2FOLH1 | |
| SCHEMBL2536422 | 0.80 | — | — | |
| SCHEMBL7437585 | 0.80 | — | — | |
| SCHEMBL415118 | 0.80 | — | — | |
| SCHEMBL442545 | 0.79 | ALDH1A1 (0.49) | GRIK1GRIK2BLMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-20080234172-A1 | Substrate care products such as fabric conditioners, tumble dryer sheets, deodorants, and fabric sprays, with capsules having a hydrogel shell encapsulating volatile care products, especially fragrances | GIVAUDAN SA (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1814975-A1 | SUBSTRATE CARE PRODUCT | Givaudan SA (CH) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006056096-A1 | SUBSTRATE CARE PRODUCT | GIVAUDAN SA (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | LPO, QDPR, TYR | CYP2C19 352/4885GABRR1 2381/4885CYP1A2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.